Benzinga | Aug 24, 2021 07:55AM EDT

Goldman Sachs Maintains Neutral on Horizon Therapeutics, Raises Price Target to $107

Goldman Sachs maintains Horizon Therapeutics (NASDAQ:HZNP) with a Neutral and raises the price target from $96 to $107.